報價延遲最少15分鐘:2024/10/31 21:08 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.825 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.22/-1.28
|
|
企業價值
262.88M
|
| 資產負債 |
|
每股賬面淨值
3.31
|
| 現金流量 |
|
現金流量率
0.00
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/10/31 21:08 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Eliem Therapeutics Inc is a clinical-stage biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Its main drug candidate is ETX-155 for major depressive disorder (MDD) and focal onset seizures (FOS). |